HCP Education - Teva
HCP Education - Teva supports providers of independent education for healthcare professionals, funding programs that strengthen clinical knowledge and decision-making in selected disease areas and biosimilars.
Funder: Teva
Due Dates: At least 60 days before the event or needed decision (whichever is earlier)
Funding Amounts: Not listed
Summary: Teva supports education that strengthens healthcare professionals’ knowledge and clinical decision-making in selected disease areas and biosimilars.
Key Information: Grant requests must come from qualified educational providers, not individuals.
Description
Teva’s HCP Education grants support independent, evidence-based education for healthcare professionals. The program considers accredited and non-accredited professional education, including symposia and web activities; accredited programs receive higher priority. Fellowships are considered case by case.
Current education objectives cover Huntington’s disease, tardive dyskinesia, schizophrenia, bipolar I disorder, and biosimilars. Priorities include improving diagnosis and understanding of disease burden, treatment options, adherence, and ongoing care. Topic-specific objectives address Huntington’s disease chorea and multidisciplinary care; tardive dyskinesia assessment and VMAT2 inhibitors; antipsychotics and long-acting injectables; and biosimilar approval, interchangeability, and adalimumab biosimilars.
